Dr. Julie Cherrington is a distinguished executive with extensive expertise in biopharmaceutical development and clinical translation of novel therapeutics. She currently serves as President and Chief Executive Officer of Arch Oncology, a clinical-stage immuno-oncology company pioneering novel anti-CD47 monoclonal antibodies for cancer treatment. Dr. Cherrington earned her B.S. and M.S. in biology and microbiology from the University of California, Davis, followed by a Ph.D. in microbiology and immunology through a joint program between the University of Minnesota and Stanford University. Her exceptional career began with progressive leadership roles at Gilead Sciences as Director of Virology, then advanced to Vice President positions at SUGEN, which became part of Pharmacia and later Pfizer, where she led preclinical research and exploratory development initiatives.
Dr. Cherrington has been instrumental in the successful development and commercialization of multiple FDA-approved therapeutics that have significantly impacted patient care across oncology and antiviral treatment domains. She served as a key contributor to landmark products including the cancer therapies SUTENT® and PALLADIA®, as well as antiviral agents VISTIDE®, VIREAD®, and HEPSERA®, demonstrating her exceptional ability to translate scientific discovery into tangible clinical benefits. Her leadership in preclinical and clinical development has directly impacted millions of patients worldwide, with SUTENT® establishing new standards of care for renal cell carcinoma and gastrointestinal stromal tumors. Throughout her career, Dr. Cherrington has demonstrated unparalleled expertise in navigating complex regulatory pathways while maintaining scientific rigor in drug development programs.
Beyond her executive leadership, Dr. Cherrington provides strategic guidance to numerous biotechnology companies as a board member of Syncona Limited, Sardona Therapeutics, Kisoji Biotechnology, MycRx, Vaxart, and Mirati Therapeutics. She actively contributes to fostering innovation in life sciences through advisory roles with California Life Sciences and academic institutions including UC San Francisco, UC Davis, and Stanford University. Dr. Cherrington is deeply committed to advancing entrepreneurship and promoting diversity in science through her involvement with initiatives such as Equalize 2020-2022. Her current work at Arch Oncology focuses on developing next-generation immuno-oncology therapies that harness the immune system's potential to transform cancer treatment paradigms.
